CORONA REMEDIES Q2 FY27 ; NET PROFIT UP 15.38% AT ₹60 CR (YOY), FLAT (QOQ)

REVENUE UP 22.16% AT ₹441 CR (YOY), UP 4.50% (QOQ) EBITDA UP 23.08% AT ₹96 CR (YOY), UP 3.23% (QOQ) MARGINS AT 21.77% VS 21.61% (YOY), 22.04% (QOQ)

CORONA REMEDIES LIMITED